Views

CrossRef citations to date

Altmetric

Original Article

A Danish Randomized Trial Comparing Breast-Preserving Therapy with Mastectomy in Mammary Carcinoma: Preliminary results

M. Blichert-Toft From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

H. Brincker From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

J. A. Andersen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

K. W. Andersen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

C. K. Axelsson From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

H. T. Mouridsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

P. Dombernowsky From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

M. Overgaard From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

C. Gadeberg From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

G. Knudsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

S. Borgeskov From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

S. Bertelsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

J. B. Knudsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

J. B. Hansen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

P. E. Poulsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

H. Willumsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

P. Schousen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

D. Froberg From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

J. Ørnsholt From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

M. Andersen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

S. Olesen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

S. Skovgaard From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

M. Øster From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

H. Schumacher From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

E. K. Lynderup From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

C. N. Holm From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

show all

Abstract

The present study comprises 847 women operated upon for invasive breast carcinoma at 19 surgical departments and enrolled in protocol DBCG-82TM from January 1983 to November 1987. Among them 662 (78%) were allocated for breast-preserving therapy or mastectomy by randomization, while 185 patients (22%) did not accept randomization. Within the randomized group 6% could not be entered into adjuvant protocols, i.e. subsequent programmes of postoperative therapy and follow-up. This left 619 evaluable patients. In the non-randomized series 26% did not fulfil the demands for entrance into the adjuvant protocols, leaving 136 evaluable patients, 60 of whom had chosen a breast-preserving operation and 76 mastectomy. In the randomized series the patients in the two treatment arms were comparable in age, menopausal status, site of tumour, pathoanatomical diameter of the tumour, number of removed axillary lymph nodes, number of metastatic axillary lymph nodes, and distribution on adjuvant regimens. Ninety per cent of the patients in the randomized group accepted the method offered, whereas 10% declined and wanted the alternate form of operation. The median follow-up period was approximately 1.75 years. The cumulative recurrence rate in the randomized group was 13% and in the non-randomized group 7%. These results are preliminary. Life-table analyses have not so far demonstrated differences in recurrence-free survival either in the randomized or the non-randomized series.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A Danish Randomized Trial Comparing Breast-Preserving Therapy with Mastectomy in Mammary Carcinoma: Preliminary results

Information for

Open access

Opportunities

Help and information

A Danish Randomized Trial Comparing Breast-Preserving Therapy with Mastectomy in Mammary Carcinoma: Preliminary results

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature